Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Urinary Tract Infections D014552 11 associated lipids
Urticaria D014581 13 associated lipids
Vertigo D014717 4 associated lipids
Vomiting D014839 21 associated lipids
Whooping Cough D014917 6 associated lipids
Wound Infection D014946 12 associated lipids
Yaws D015001 4 associated lipids
Superinfection D015163 3 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Weight Gain D015430 101 associated lipids
Weight Loss D015431 56 associated lipids
Ethmoid Sinusitis D015521 2 associated lipids
Frontal Sinusitis D015522 1 associated lipids
Corneal Edema D015715 3 associated lipids
Erythema Chronicum Migrans D015787 3 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Vaginosis, Bacterial D016585 10 associated lipids
Pneumocystis Infections D016720 1 associated lipids
Leishmaniasis, Cutaneous D016773 6 associated lipids
Malaria, Falciparum D016778 22 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Neisseriaceae Infections D016870 3 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Pelvic Pain D017699 7 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Granuloma, Pyogenic D017789 2 associated lipids
Furcation Defects D017823 1 associated lipids
T-Lymphocytopenia, Idiopathic CD4-Positive D018344 1 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Parasitemia D018512 5 associated lipids
Abdominal Abscess D018784 2 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Pseudolymphoma D019310 1 associated lipids
Pouchitis D019449 3 associated lipids
Syncope, Vasovagal D019462 1 associated lipids
Acquired Hyperostosis Syndrome D020083 1 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Focal Nodular Hyperplasia D020518 1 associated lipids
Multiple Sclerosis, Relapsing-Remitting D020529 7 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Evans LA et al. Predicting injection site muscle damage. III: Evaluation of intramuscular formulations in the L6 cell model. 1996 Pharm. Res. pmid:8899856
Segreti J et al. In vitro activity of macrolides against intracellular Legionella pneumophila. 1996 Diagn. Microbiol. Infect. Dis. pmid:8902407
Gastearena I et al. Determination of the alpha1-acid glycoprotein binding of azithromycin in vitro by equilibrium dialysis. 1995 J Chemother pmid:8904095
Domingo S et al. Significance of environmental conditions (pH and serum) on the in vitro potency of azithromycin against Brucella melitensis. 1995 J Chemother pmid:8904096
Wendel TD 1-day azithromycin was as effective as 7-day doxycycline for nongonococcal urethritis syndrome in men. 1996 Nov-Dec ACP J. Club pmid:8912627
Luke DR et al. Safety, toleration, and pharmacokinetics of intravenous azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8913468
Olsen KM et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. 1996 Antimicrob. Agents Chemother. pmid:8913469
Kuo CC et al. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8913488
Aoyama T et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. 1996 J. Pediatr. pmid:8917247
O'Doherty B Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group. 1996 Eur. J. Clin. Microbiol. Infect. Dis. pmid:8922571
Griffith DE et al. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. 1996 Clin. Infect. Dis. pmid:8922790
Chulig I [Pharmacokinetic profile of azithromycin. Role in the treatment of genital Chlamydia infections]. 1996 Antibiot. Khimioter. pmid:8929112
Kuznetsova SM ["Sumamed in the treatment of urogenital infections"]. 1996 Antibiot. Khimioter. pmid:8929115
Skripkin IuK et al. [The problem of diagnosis and treatment of urogenital chlamydiosis in Russia]. 1996 Antibiot. Khimioter. pmid:8929120
Vasil'ev MM and Gazarian IIu [Clinico-laboratory evaluation of the effectiveness of azithromycin in the treatment of patients with Chlamydia and mixed Chlamydia-gonorrhea infections]. 1996 Antibiot. Khimioter. pmid:8929122
Meloni G and Meloni T Azithromycin vs. doxycycline for Mediterranean spotted fever. 1996 Pediatr. Infect. Dis. J. pmid:8933556
Jackson MA et al. Breakthrough sepsis in macrolide-resistant pneumococcal infection. 1996 Pediatr. Infect. Dis. J. pmid:8933560
Keysary A et al. The in-vitro anti-rickettsial activity of macrolides. 1996 J. Antimicrob. Chemother. pmid:8937968
Mein J et al. Donovanosis: sequelae of severe disease and successful azithromycin treatment. 1996 Int J STD AIDS pmid:8940677
Hoque S et al. Rhodococcus equi in CAPD-associated peritonitis treated with azithromycin. 1996 Nephrol. Dial. Transplant. pmid:8941608
Wiselka MJ et al. Response to oral and intravenous azithromycin in a patient with toxoplasma encephalitis and AIDS. 1996 J. Infect. pmid:8945715
Tansey MJ and Moe JB Severe neutropenia and prophylactic doses of rifabutin. 1996 Lancet pmid:8950911
Sefton AM et al. Azithromycin in the treatment of periodontal disease. Effect on microbial flora. 1996 J. Clin. Periodontol. pmid:8951627
Griffith DE et al. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. 1996 Clin. Infect. Dis. pmid:8953085
Brihmer C et al. Efficacy and safety of azithromycin versus lymecyline in the treatment of genital chlamydial infections in women. 1996 Scand. J. Infect. Dis. pmid:8953672
Van Bambeke F et al. Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. 1996 Eur. J. Pharmacol. pmid:8957238
Montenez JP et al. Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies. 1996 Eur. J. Pharmacol. pmid:8957239
Ripa S et al. A linear model for the pharmacokinetics of azithromycin in healthy volunteers. 1996 Nov-Dec Chemotherapy pmid:8957574
Peeling RW and Brunham RC Chlamydiae as pathogens: new species and new issues. 1996 Oct-Dec Emerging Infect. Dis. pmid:8969247
Cammarota G et al. Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. 1996 Aliment. Pharmacol. Ther. pmid:8971300
Pilotto A et al. Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. 1996 Aliment. Pharmacol. Ther. pmid:8971305
Andenaes K et al. Preoperative bacterial colonization and its influence on postoperative wound infections in plastic surgery. 1996 J. Hosp. Infect. pmid:8971618
Pozniak A and Nelson MR Against the proposition: all patients with advanced HIV disease should be offered rifabutin prophylaxis. 1996 Genitourin Med pmid:8976832
Schwartz RA et al. Bacillary angiomatosis in an HIV seronegative patient on systemic steroid therapy. 1996 Br. J. Dermatol. pmid:8977724
Vranes J Effect of subinhibitory concentrations of ceftazidime, ciprofloxacin, and azithromycin on the hemagglutination and adherence of uropathogenic Escherichia coli strains. 1996 May-Jun Chemotherapy pmid:8983884
Ichimiya T et al. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. 1996 May-Jun Chemotherapy pmid:8983885
Galova K et al. Multicenter randomized study of two once daily regimens in the initial management of community-acquired respiratory tract infections in 163 children: azithromycin versus ceftibuten. 1996 May-Jun Chemotherapy pmid:8983893
Akita H et al. [Bacteriological, pharmacokinetic and clinical evaluation of azithromycin in the pediatric field]. 1996 Jpn J Antibiot pmid:8986553
Nishimura T et al. [Clinical evaluation of azithromycin in pediatric infections]. 1996 Jpn J Antibiot pmid:8986554
Haruta T and Kobayashi Y [Therapeutic efficacy of azithromycin in pediatrics]. 1996 Jpn J Antibiot pmid:8986555
Kuroda Y and Ito M [Therapy with azithromycin in pediatric infections]. 1996 Jpn J Antibiot pmid:8986556
Okamoto T and Sekiguchi T [Clinical studies on azithromycin in pediatrics]. 1996 Jpn J Antibiot pmid:8986557
Toyonaga Y et al. [Pharmacokinetic and clinical evaluation of azithromycin using fine granules or capsules in the pediatric patients]. 1996 Jpn J Antibiot pmid:8988410
Okumura A and Kuno K [Pharmacokinetic and clinical evaluation of azithromycin in pediatrics]. 1996 Jpn J Antibiot pmid:8988411
Kobayashi Y et al. [Clinical study of a macrolide antibiotic, azithromycin, in pediatric patients]. 1996 Jpn J Antibiot pmid:8988412
Furukawa S and Okada T [A clinical evaluation of azithromycin in the treatment of pediatric infection]. 1996 Jpn J Antibiot pmid:8988413
Okada T et al. [Pharmacokinetic and clinical evaluations of azithromycin in the pediatric field]. 1996 Jpn J Antibiot pmid:8988414
Ishida Y et al. [Pharmacokinetic and clinical evaluation of azithromycin in pediatric infections]. 1996 Jpn J Antibiot pmid:8988415
Ohtsuka Y et al. [Pharmacokinetic and clinical studies on azithromycin in children]. 1996 Jpn J Antibiot pmid:8988416
Tseng AL et al. Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus. 1997 Clin. Infect. Dis. pmid:8994766
Hayle R et al. Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis. 1996 Eur. J. Clin. Microbiol. Infect. Dis. pmid:8997555
Carlin EM and Barton SE Azithromycin as a cost-effective treatment for nongonococcal urethritis in men. 1997 Sex Transm Dis pmid:9018784
Berg-Candolfi M and Candolfi E Depression of the N-demethylation of erythromycin, azithromycin, clarithromycin and clindamycin in murine Toxoplasma infection. 1996 Int. J. Parasitol. pmid:9024879
Caselli M et al. Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. 1997 Eur J Gastroenterol Hepatol pmid:9031898
Bedos JP and Veber B [Lower respiratory infections: predictive factors of therapeutic response]. 1996 Rev Pneumol Clin pmid:9033917
Zuck P [Efficacy of a 5-day treatment with an azalide (azithromycin) in superinfections of chronic bronchitis]. 1996 Rev Pneumol Clin pmid:9033919
Arévalo Morles C et al. Donovanosis: treatment with azithromycin. 1997 Int J STD AIDS pmid:9043983
Fuchs PC et al. Effect of minor pH changes on the in-vitro activity of azithromycin and clarithromycin. 1997 J. Antimicrob. Chemother. pmid:9044039
Tursi A et al. What is the best azithromycin-based therapy for Helicobacter pylori infection? 1997 J. Antimicrob. Chemother. pmid:9044040
MashkilleÄ­son AL [The treatment of early syphilis today]. 1996 Ter. Arkh. pmid:9045378
Mosby JA Treating acute bronchitis with azithromycin. 1997 Am Fam Physician pmid:9054218
Adhikari P et al. Evaluation of safety and efficacy of azithromycin in lower respiratory tract infections (LRTI) 1996 Indian J Med Sci pmid:9057364
Thylefors B Trachoma--new opportunities to tackle an old problem. 1996 Br J Ophthalmol pmid:9059262
Blanshard C et al. Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis. 1997 Int J STD AIDS pmid:9061412
Herrera-Insúa I et al. Synergistic effect of azithromycin on the phagocytic killing of Staphylococcus aureus by human polymorphonuclear leukocytes. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9063667
Pascual A et al. Azithromycin uptake by tissue cultured epithelial cells. 1997 J. Antimicrob. Chemother. pmid:9069561
Handsfield HH et al. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. 1994 Mar-Apr Sex Transm Dis pmid:9071422
Tajima T et al. [Pharmacokinetic, bacteriological and clinical studies on azithromycin in children]. 1997 Jpn J Antibiot pmid:9100080
Kitamura K et al. [Pharmacokinetic and clinical evaluation of azithromycin in the pediatric field]. 1997 Jpn J Antibiot pmid:9100081
Fietta A et al. Inhibition of intracellular growth of Staphylococcus aureus by exposure of infected human monocytes to clarithromycin and azithromycin. 1997 J Chemother pmid:9106013
Fietta A et al. Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes. 1997 J Chemother pmid:9106014
Ficnar B et al. Azithromycin: 3-day versus 5-day course in the treatment of respiratory tract infections in children. Croatian Azithromycin Study Group. 1997 J Chemother pmid:9106016
Klein JO History of macrolide use in pediatrics. 1997 Pediatr. Infect. Dis. J. pmid:9109154
McCracken GH Microbiologic activity of the newer macrolide antibiotics. 1997 Pediatr. Infect. Dis. J. pmid:9109155
Nightingale CH Pharmacokinetics and pharmacodynamics of newer macrolides. 1997 Pediatr. Infect. Dis. J. pmid:9109156
Tarlow MJ Macrolides in the management of streptococcal pharyngitis/tonsillitis. 1997 Pediatr. Infect. Dis. J. pmid:9109157
Block SL Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. 1997 Pediatr. Infect. Dis. J. pmid:9109158
Tarlow MJ et al. Future indications for macrolides. 1997 Pediatr. Infect. Dis. J. pmid:9109159
Dawson CR et al. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. 1997 Clin. Infect. Dis. pmid:9114186
Kavukçu S et al. Hypothermia from azithromycin. 1997 J. Toxicol. Clin. Toxicol. pmid:9120898
Hultén K et al. New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. 1996 Antimicrob. Agents Chemother. pmid:9124830
Marchisio P et al. Comparative study of once-weekly azithromycin and once-daily amoxicillin treatments in prevention of recurrent acute otitis media in children. 1996 Antimicrob. Agents Chemother. pmid:9124831
Roord JJ et al. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. 1996 Antimicrob. Agents Chemother. pmid:9124837
Jones RN and Biedenbach DJ Antimicrobial activity of RU-66647, a new ketolide. 1997 Jan-Feb Diagn. Microbiol. Infect. Dis. pmid:9127099
Khan WA et al. Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. 1997 Ann. Intern. Med. pmid:9139555
Brown BA et al. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. 1997 Clin. Infect. Dis. pmid:9142801
Littlewood-Evans AJ et al. Effect of combination therapy of rifampicin and azithromycin on TNF levels during a rat model of chronic osteomyelitis. 1997 J. Antimicrob. Chemother. pmid:9145822
Worth S et al. Quality control guidelines for amoxicillin, amoxicillin-clavulanate, azithromycin, piperacillin-tazobactam, roxithromycin, ticarcillin, ticarcillin-clavulanate, trovafloxacin (CP 99,219), U-100592, and U-100766 for various National Committee for Clinical Laboratory Standards susceptibility testing methods. Results from multicenter trials. 1996 Diagn. Microbiol. Infect. Dis. pmid:9147914
Trotta M et al. [Azithromycin combined with pyrimethamine in the treatment of neurotoxoplasmosis, in an AIDS patient]. 1997 Minerva Med. pmid:9148227
Yasin RM et al. Comparison of E-test with agar dilution methods in testing susceptibility of N. gonorrhoeae to azithromycin. 1997 Sex Transm Dis pmid:9153733
Pacifico L and Chiesa C Efficacy of three-day azithromycin vs. ten-day penicillin V in the treatment of streptococcal pharyngitis. 1997 Pediatr. Infect. Dis. J. pmid:9154566
Fernandez-Obregon AC Azithromycin for the treatment of acne. 1997 Int. J. Dermatol. pmid:9159021
Nilius AM et al. Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH. 1997 J. Clin. Microbiol. pmid:9163435
Kuzman I et al. Azithromycin in the treatment of pneumonias caused by Chlamydia spp: a retrospective study. 1996 Int J Clin Pharmacol Res pmid:9172008
Rodvold KA et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. 1997 Antimicrob. Agents Chemother. pmid:9174209
Young H et al. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. 1997 Int J STD AIDS pmid:9175650
Hulten K et al. In-vitro activity of azithromycin in against intracellular Helicobacter pylori. 1996 J. Antimicrob. Chemother. pmid:9182105
Paul TR et al. Delivery of azithromycin to Chlamydia trachomatis-infected polarized human endometrial epithelial cells by polymorphonuclear leucocytes. 1997 J. Antimicrob. Chemother. pmid:9184362
Na-Bangchang K et al. Activity of artemether-azithromycin versus artemether-doxycycline in the treatment of multiple drug resistant falciparum malaria. 1996 Southeast Asian J. Trop. Med. Public Health pmid:9185262
Waites K et al. In vitro activities of oral antimicrobial agents against penicillin-resistant Streptococcus pneumoniae: implications for outpatient treatment. 1997 South. Med. J. pmid:9191739